Successful Rechallenge with Gefitinib for an Initial Erlotinib-Responder with Advanced Lung Adenocarcinoma / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
;
: 286-290, 2011.
Artículo
en Coreano
| WPRIM
| ID: wpr-45123
ABSTRACT
Although failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) is generally believed to be associated with cross-resistance to other EGFR TKI, the benefit of administering erlotinib as a second EGFR TKI after resistance of gefitinib as the first TKI has been well known. However, good response to gefitinib after an initial response to erlotinib has been rare. We report that a 45-year-old woman (never smoked), with lung adenocarcinoma and EGFR mutation, showed an initial response to erlotinib, and then responded to gefitinib again.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Quinazolinas
/
Proteínas Tirosina Quinasas
/
Adenocarcinoma
/
Receptores ErbB
/
Clorhidrato de Erlotinib
/
Pulmón
/
Neoplasias Pulmonares
Límite:
Femenino
/
Humanos
Idioma:
Coreano
Revista:
Tuberculosis and Respiratory Diseases
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS